Wikipedia

User:Berchanhimez/COVtable

< User:Berchanhimez
Vaccines authorized for emergency use or approved for full use
Vaccine Type (technology) Doses, interval Storage Trials Authorization
Oxford/AstraZeneca[1][a][b][5][6][7] Vector[5] 2 doses
4–12 weeks[8] 		2–8 °C[9] Phase III User:Berchanhimez/CovidVacNum
Pfizer/BioNTech[10][11][12]
BioNTech, Pfizer 		modRNA[10] 2 doses
3–4 weeks[13][c] 		-70±10 °C[d]
(ULT) 		Phase III User:Berchanhimez/CovidVacNum
Sputnik V (Gam-COVID-Vac)
Gamaleya Research Institute of Epidemiology and Microbiology 		Vector[18] 2 doses
3 weeks[19] 		≤-18 °C[e]
(freezer) 		Phase III User:Berchanhimez/CovidVacNum
Moderna[21][22]
Moderna, NIAID, BARDA, CEPI 		modRNA[23] 2 doses
4 weeks[24][c] 		-20±5 °C[25]
(freezer) 		Phase III User:Berchanhimez/CovidVacNum
BBIBP-CorV[26]
Sinopharm 		Inactivated[26] 2 doses
3–4 weeks[27] 		2–8 °C[28] Phase III User:Berchanhimez/CovidVacNum
Johnson & Johnson[29][30]
Janssen Vaccines (Johnson & Johnson), BIDMC 		Vector[31] 1 dose[32] 2–8 °C[32] Phase III User:Berchanhimez/CovidVacNum
CoronaVac[33][34][35]
Sinovac 		Inactivated[33] 2 doses
2 weeks[36] 		2–8 °C[37] Phase III User:Berchanhimez/CovidVacNum
BBV152 (Covaxin)
Bharat Biotech 		Inactivated[38] 2 doses
4 weeks[39] 		2–8 °C[39] Phase III User:Berchanhimez/CovidVacNum
Ad5-nCoV (Convidecia)
CanSino Biologics, Academy of Military Medical Sciences 		Vector[40] 1 dose[41] 2–8 °C[41] Phase III User:Berchanhimez/CovidVacNum
EpiVacCorona[42]
Vector Institute 		Subunit (peptide)[42] 2 doses
3 weeks[42] 		2–8 °C[43] Phase III User:Berchanhimez/CovidVacNum
ZF2001 (RBD-Dimer)[44]
Anhui Zhifei Longcom 		Subunit (recombinant) 3 doses
30 days[45][46] 		Phase III User:Berchanhimez/CovidVacNum
WIBP-CorV
Sinopharm: Wuhan Institute of Biological Products 		Inactivated 1 dose[citation needed] Phase III User:Berchanhimez/CovidVacNum
CoviVac[47]
The Chumakov Centre at the Russian Academy of Sciences 		Inactivated[48] 2 doses
2 weeks[49] 		2–8 °C[49] Phase III User:Berchanhimez/CovidVacNum
  1. ^ "Vaxzevria (previously COVID-19 Vaccine AstraZeneca) EPAR". European Medicines Agency (EMA).
  2. ^ "AstraZeneca & Serum Institute of India sign licensing deal for 1 million doses of Oxford vaccine". The Economic Times. Retrieved 15 June 2020.
  3. ^ "Covid-19 vaccine: Serum Institute signs up for 100 million doses of vaccines for India, low and middle-income countries". The Financial Express. 7 August 2020.
  4. ^ Walsh N, Shelley J, Duwe E, Bonnett W (27 July 2020). "The world's hopes for a coronavirus vaccine may run in these health care workers' veins". São Paulo: CNN. Archived from the original on 3 August 2020. Retrieved 3 August 2020.
  5. ^ a b "Investigating a Vaccine Against COVID-19". ClinicalTrials.gov. United States National Library of Medicine. 26 May 2020. NCT04400838. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  6. ^ "A Phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19". EU Clinical Trials Register. European Union. 21 April 2020. EudraCT 2020-001228-32. Archived from the original on 5 October 2020. Retrieved 3 August 2020.
  7. ^ O'Reilly P (26 May 2020). "A Phase III study to investigate a vaccine against COVID-19". ISRCTN. doi:10.1186/ISRCTN89951424. ISRCTN89951424.
  8. ^ Gallagher J, Triggle N (30 December 2020). "Covid-19: Oxford-AstraZeneca vaccine approved for use in UK". BBC. Retrieved 5 March 2020.
  9. ^ AstraZeneca COVID-19 Vaccine (PDF) (Product Monograph). AstraZeneca. 26 February 2021. 244627. Retrieved 5 March 2021.
  10. ^ a b "Regulatory Decision Summary – Pfizer-BioNTech COVID-19 Vaccine". Health Canada, Government of Canada. 9 December 2020. Retrieved 9 December 2020.
  11. ^ "Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults". ClinicalTrials.gov. United States National Library of Medicine. 30 April 2020. NCT04368728. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  12. ^ "A Multi-site Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults". EU Clinical Trials Register. European Union. 14 April 2020. EudraCT 2020-001038-36. Archived from the original on 22 April 2020. Retrieved 22 April 2020.
  13. ^ Farge E, Revill J (5 January 2021). "WHO recommends two doses of Pfizer COVID-19 vaccine within 21–28 days". Reuters. Geneva. Retrieved 5 March 2021.
  14. ^ Keaten J (8 January 2021). "WHO: Amid short supplies, vaccine doses can be 6 weeks apart". Associated Press. Geneva. Retrieved 6 March 2021.
  15. ^ "COVID vaccine: Moderna shots can be 6 weeks apart, WHO says". Deutsche Welle. 26 January 2021. Retrieved 6 March 2021.
  16. ^ "Coronavirus (COVID-19) Update: FDA Allows More Flexible Storage, Transportation Conditions for Pfizer-BioNTech COVID-19 Vaccine" (Press release). Food and Drug Administration (FDA). 25 February 2021. Retrieved 5 March 2021.
  17. ^ "Pfizer-BioNTech COVID-19 Vaccine EUA Fact Sheet for Healthcare Providers" (PDF). Pfizer. 25 February 2021. Retrieved 25 February 2021.
  18. ^ "An Open Study of the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac" Vaccine Against COVID-19". ClinicalTrials.gov. United States National Library of Medicine. 17 June 2020. NCT04436471. Retrieved 5 March 2021.
  19. ^ Jones I, Roy P (February 2021). "Sputnik V COVID-19 vaccine candidate appears safe and effective". Lancet. 397 (10275): 642–643. doi:10.1016/S0140-6736(21)00191-4. PMC 7906719. PMID 33545098.
  20. ^ Sagdiev R, Ivanova P (16 November 2020). "Russia focuses on freeze-dried vaccine doses as transport fix". Reuters. Moscow. Retrieved 5 March 2021.
  21. ^ "A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19". ClinicalTrials.gov. United States National Library of Medicine. 14 July 2020. NCT04470427. Archived from the original on 11 October 2020. Retrieved 27 July 2020.
  22. ^ Palca J (27 July 2020). "COVID-19 vaccine candidate heads to widespread testing in U.S." NPR. Archived from the original on 11 October 2020. Retrieved 27 July 2020.
  23. ^ "Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)". ClinicalTrials.gov. United States National Library of Medicine. 16 March 2020. NCT04283461. Retrieved 5 March 2021.
  24. ^ "WHO experts issue recommendations on Moderna COVID-19 vaccine". Reuters. Geneva. 26 January 2021. Retrieved 5 March 2021.
  25. ^ Fact Sheet for Healthcare Providers Administering Vaccine (Fact sheet). Food and Drug Administration. December 2020. Retrieved 5 March 2021.
  26. ^ a b Chen W, Al Kaabi N (18 July 2020). "A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells)". Chinese Clinical Trial Registry. Retrieved 15 August 2020.
  27. ^ Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. (January 2021). "Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial". The Lancet. Infectious Diseases. 21 (1): 39–51. doi:10.1016/S1473-3099(20)30831-8. PMC 7561304. PMID 33069281.
  28. ^ Elbahrawy F, Lyu D, Omar A, Che C, Paton J (9 December 2020). "China State-Backed Covid Vaccine Has 86% Efficacy, UAE Says". Bloomberg News. Retrieved 5 March 2020. CNBG's vaccine can be transported and stored at normal refrigerated temperatures.
  29. ^ "A Study of Ad26.COV2.S in Adults". ClinicalTrials.gov. 4 August 2020. Archived from the original on 16 September 2020. Retrieved 23 August 2020.
  30. ^ "A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants". ClinicalTrials.gov. US National Library of Medicine. Archived from the original on 26 September 2020.
  31. ^ Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19 (Briefing). Food and Drug Administration. 26 February 2021. p. 6. Retrieved 6 March 2021. The vaccine, known as Ad26.COV2.S, is a replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding a stabilized variant of the SARS-CoV-2 S protein.
  32. ^ a b Ledford H (January 2021). "J&J's one-shot COVID vaccine offers hope for faster protection". Nature. doi:10.1038/d41586-021-00119-7. PMID 33526898.
  33. ^ a b "Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection (COVID-19) (Renqiu)". ClinicalTrials.gov. United States National Library of Medicine. 12 May 2020. NCT04383574. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  34. ^ "Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals (PROFISCOV)". ClinicalTrials.gov. United States National Library of Medicine. 2 July 2020. NCT04456595. Archived from the original on 11 October 2020. Retrieved 3 August 2020.
  35. ^ PT. Bio Farma (10 August 2020). "A Phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-COV-2 inactivated vaccine in healthy adults aged 18–59 years in Indonesia". Registri Penyakit Indonesia. Retrieved 15 August 2020.
  36. ^ "Sinovac says COVID-19 vaccine effective in preventing hospitalization, death". Reuters. 5 February 2021. Retrieved 5 March 2021.
  37. ^ Tan Y (14 January 2021). "Covid: What do we know about China's coronavirus vaccines?". BBC. Retrieved 5 March 2020.
  38. ^ "Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers". ClinicalTrials.gov. NCT04471519.
  39. ^ a b "Covishield and Covaxin: What we know about India's Covid-19 vaccines". BBC. 4 March 2021. Retrieved 5 March 2020. The two doses are given four weeks apart. The vaccine can be stored at 2C to 8C.
  40. ^ Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. (August 2020). "Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial". Lancet. 396 (10249): 479–488. doi:10.1016/s0140-6736(20)31605-6. PMC 7836858. PMID 32702299. {{cite journal}}: Unknown parameter |lay-url= ignored (help)
  41. ^ a b Peshimam G, Farooq U (8 February 2021). "CanSinoBIO's COVID-19 vaccine 65.7% effective in global trials, Pakistan official says". Reuters. Islamabad. Retrieved 5 March 2021. its single-dose regimen and normal refrigerator storage requirement could make it a favourable option for many countries
  42. ^ a b c Ryzhikov AB, Ryzhikov EA, Bogryantseva MP, Usova SV, Danilenko ED, Nechaeva EA, Pyankov OV, Pyankova OG, Gudymo AS, Bodnev SA, Onkhonova GS, Sleptsova ES, Kuzubov VI, Ryndyuk NN, Ginko ZI, Petrov VN, Moiseeva AA, Torzhkova PY, Pyankov SA, Tregubchak TV, Antonec DV, Gavrilova EV, Maksyutov RA (2021). "A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the "EpiVacCorona" Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II)". Russian Journal of Infection and Immunity. 11 (2): 283–296. doi:10.15789/2220-7619-ASB-1699.
  43. ^ Benedyczak J (12 February 2021). Russia's Problems in the Vaccine Race (Bulletin). Polish Institute of International Affairs. Retrieved 6 March 2021. the Sputnik V and EpiVacCorona can be transported and stored at temperatures of +2 to + 8° C
  44. ^ Cite error: The named reference london was invoked but never defined (see the help page).
  45. ^ Cite error: The named reference NCT04646590 was invoked but never defined (see the help page).
  46. ^ "China's CAS COVID-19 vaccine induces immune response in mid-stage tests". Reuters. Beijing. 23 December 2020. Retrieved 8 March 2021.
  47. ^ "Briefing with Deputy Prime Minister Tatyana Golikova, Health Minister Mikhail Murashko and Head of Rospotrebnadzor Anna Popova". Government of Russia. 18 January 2021. Retrieved 20 February 2021.
  48. ^ Ryumin A (20 February 2021). "Russia registers its third COVID-19 vaccine CoviVac". TASS. Moscow. Retrieved 6 March 2021.
  49. ^ a b Ivanova P (8 February 2021). "Russia approves its third COVID-19 vaccine, CoviVac". Reuters. Moscow. Retrieved 5 March 2021. The CoviVac shot is given in two doses, 14 days apart. It is transported and stored at normal fridge temperatures, of 2 to 8 degrees Celsius (35.6 to 46.4 Fahrenheit), Deputy Prime Minister Tatiana Golikova said in a government briefing in January.


Cite error: There are <ref group=lower-alpha> tags or {{efn}} templates on this page, but the references will not show without a {{reflist|group=lower-alpha}} template or {{notelist}} template (see the help page).

Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Berchanhimez/COVtable&oldid=1146386039"